ID: ALA210633

Max Phase: Preclinical

Molecular Formula: C26H21N5O2

Molecular Weight: 435.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCc1cccc(-c2cccc(-c3cc4c[nH]ccc-4n3)c2O)c1)Nc1cccnc1

Standard InChI:  InChI=1S/C26H21N5O2/c32-25-21(7-2-8-22(25)24-13-19-15-28-11-9-23(19)31-24)18-5-1-4-17(12-18)14-29-26(33)30-20-6-3-10-27-16-20/h1-13,15-16,28,32H,14H2,(H2,29,30,33)

Standard InChI Key:  CXUPMQGDURWIQV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 435.49

Molecular Weight (Monoisotopic): 435.1695

AlogP: 5.27

#Rotatable Bonds: 5

Polar Surface Area: 102.93

Molecular Species: NEUTRAL

HBA: 4

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 8.92

CX Basic pKa: 4.54

CX LogP: 4.22

CX LogD: 4.21

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.30

Np Likeness Score: -1.14

References

1. Riggs JR, Hu H, Kolesnikov A, Leahy EM, Wesson KE, Shrader WD, Vijaykumar D, Wahl TA, Tong Z, Sprengeler PA, Green MJ, Yu C, Katz BA, Sanford E, Nguyen M, Cabuslay R, Young WB..  (2006)  Novel 5-azaindole factor VIIa inhibitors.,  16  (12): [PMID:16621549] [10.1016/j.bmcl.2006.03.049]

Source

Source(1):

• Scientific Literature